CQS Cayman LP lowered its stake in shares of Walgreens Boots Alliance, Inc. (NASDAQ:WBA) by 18.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 11,000 shares of the pharmacy operator’s stock after selling 2,500 shares during the quarter. CQS Cayman LP’s holdings in Walgreens Boots Alliance were worth $861,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in WBA. Pathstone Family Office LLC grew its position in Walgreens Boots Alliance by 226.6% in the 2nd quarter. Pathstone Family Office LLC now owns 1,179 shares of the pharmacy operator’s stock valued at $1,969,000 after acquiring an additional 818 shares during the last quarter. Hudock Capital Group LLC grew its position in Walgreens Boots Alliance by 0.5% in the 2nd quarter. Hudock Capital Group LLC now owns 1,306 shares of the pharmacy operator’s stock valued at $102,000 after acquiring an additional 6 shares during the last quarter. Reilly Financial Advisors LLC grew its position in Walgreens Boots Alliance by 7.9% in the 2nd quarter. Reilly Financial Advisors LLC now owns 1,367 shares of the pharmacy operator’s stock valued at $107,000 after acquiring an additional 100 shares during the last quarter. Founders Capital Management bought a new position in Walgreens Boots Alliance in the 1st quarter valued at $161,000. Finally, Hanson McClain Inc. grew its position in Walgreens Boots Alliance by 4.6% in the 2nd quarter. Hanson McClain Inc. now owns 1,987 shares of the pharmacy operator’s stock valued at $156,000 after acquiring an additional 87 shares during the last quarter. 63.35% of the stock is currently owned by hedge funds and other institutional investors.
Walgreens Boots Alliance, Inc. (WBA) opened at $70.78 on Tuesday. Walgreens Boots Alliance, Inc. has a 1 year low of $63.82 and a 1 year high of $88.00. The stock has a market capitalization of $71,460.00, a PE ratio of 13.97, a P/E/G ratio of 1.27 and a beta of 1.20. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.59 and a current ratio of 1.07.
Walgreens Boots Alliance (NASDAQ:WBA) last announced its earnings results on Wednesday, October 25th. The pharmacy operator reported $1.31 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.21 by $0.10. Walgreens Boots Alliance had a return on equity of 18.36% and a net margin of 3.45%. The company had revenue of $30.15 billion for the quarter, compared to analyst estimates of $29.93 billion. During the same period in the prior year, the company posted $1.07 EPS. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. equities analysts predict that Walgreens Boots Alliance, Inc. will post 5.55 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Monday, November 13th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 2.26%. The ex-dividend date is Friday, November 10th. Walgreens Boots Alliance’s dividend payout ratio is currently 42.33%.
Walgreens Boots Alliance declared that its Board of Directors has authorized a share repurchase plan on Wednesday, October 25th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the pharmacy operator to repurchase shares of its stock through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its shares are undervalued.
In other Walgreens Boots Alliance news, Director John Anthony Lederer bought 20,000 shares of Walgreens Boots Alliance stock in a transaction that occurred on Thursday, October 26th. The shares were bought at an average cost of $67.00 per share, with a total value of $1,340,000.00. Following the transaction, the director now directly owns 50,000 shares of the company’s stock, valued at approximately $3,350,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William C. Foote sold 2,736 shares of the company’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $67.37, for a total value of $184,324.32. Following the transaction, the director now directly owns 16,415 shares in the company, valued at $1,105,878.55. The disclosure for this sale can be found here. Corporate insiders own 13.50% of the company’s stock.
WARNING: This news story was originally posted by Week Herald and is owned by of Week Herald. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://weekherald.com/2017/11/21/cqs-cayman-lp-has-861000-stake-in-walgreens-boots-alliance-inc-wba.html.
Several brokerages have commented on WBA. Royal Bank Of Canada began coverage on Walgreens Boots Alliance in a research report on Tuesday, September 19th. They issued an “outperform” rating and a $96.00 price objective on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $94.00 price objective on shares of Walgreens Boots Alliance in a research report on Saturday, September 16th. BidaskClub downgraded Walgreens Boots Alliance from a “hold” rating to a “sell” rating in a research report on Tuesday, September 12th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $95.00 price objective on shares of Walgreens Boots Alliance in a research report on Thursday, September 7th. Finally, UBS AG reaffirmed a “buy” rating and issued a $96.00 price objective (down previously from $97.00) on shares of Walgreens Boots Alliance in a research report on Wednesday, August 23rd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the company’s stock. Walgreens Boots Alliance presently has a consensus rating of “Buy” and a consensus target price of $87.63.
Walgreens Boots Alliance Company Profile
Walgreens Boots Alliance, Inc (Walgreens Boots Alliance) is a holding company. The Company is a global pharmacy-led, health and wellbeing enterprise. Walgreens Boots Alliance operates through three divisions, including Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Company’s products are marketed under a number of brands, which include No7, the Botanics range, Almus (generic medicines), Boots Pharmaceuticals and Soap & Glory (bathing and beauty brand).
Receive News & Ratings for Walgreens Boots Alliance Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walgreens Boots Alliance Inc. and related companies with MarketBeat.com's FREE daily email newsletter.